

Publication of 2010 Annual Report and Notice of AGM

London, May 18, 2011 – Silence Therapeutics plc (AIM: SLN) (“Silence” or “the Company”) announces that it has today published and sent to shareholders the Annual Report and Accounts for the year ended 31 December 2010. Notice of Annual General Meeting ("AGM") and Form of Proxy have also been sent to shareholders. Copies are available online at the Company’s website (www.silence-therapeutics.com).

Silence’s AGM will be held on Monday 13 June 2011. The meeting will be held at Silence’s offices at the Royal Institute of Great Britain, 21 Albemarle Street, London W1S 4BS, commencing at 11.00 am.

--Ends--

For further information, please contact:

<p>Silence Therapeutics Phil Haworth/Max Herrmann +1 (650) 855-1514/+44 20 7491 6520 p.haworth@silence-therapeutics.com/ m.herrmann@silence-therapeutics.com</p>	<p>Singer Capital Markets Shaun Dobson/Claes Spång +44 20 32057500 shaun.dobson@singercm.com claes.spang@singercm.com</p>
<p>Vida Communication (US) Tim Brons (media)/Stephanie Diaz (investors) +1 (415) 675-7400 tbrons@vidacommunication.com sdiaz@vidacommunication.com</p>	<p>M:Communications (Europe) Katja Toon / Emma Thompson +44 20 7920 2345 / +44 20 7920 2342 healthcare@mcomgroup.com</p>

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs. Silence’s unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The Company’s lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

###